Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma

TY - JOUR

T1 - Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma

AU - Diaz, John P.

AU - Tew, William P.

AU - Zivanovic, Oliver

AU - Konner, Jason

AU - Sabbatini, Paul J.

AU - Santos, Lisa A. dos

AU - Abu-Rustum, Nadeem R.

AU - Chi, Dennis S.

AU - Aghajanian, Carol

AU - Barakat, Richard R.

N1 - Six (4%) of 160 patients with ovarian carcinoma who had been treated with bevacizumab developed GI perforations, with a median of 4 (range, 2-8) previous cytotoxic regimens. The median serum CA-125 at the start of treatment was 228 U/mL (range, 50-3106 U/mL). The median number of bevacizumab cycles prior to perforation was 10.5 (range, 2-20).

PY - 2010/3/1

Y1 - 2010/3/1

UR - https://www.sciencedirect.com/science/article/pii/S0090825809009585

U2 - 10.1016/j.ygyno.2009.11.017

DO - 10.1016/j.ygyno.2009.11.017

M3 - Article

VL - 116

JO - Gynecologic Oncology

JF - Gynecologic Oncology

ER -